Net Income
Net Income (NCI)
W.R. Berkley Net Income (NCI) decreased by 61.7% to $359.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 261.7%, from -$222.00K to $359.00K.
Analysis
StatementIncome Statement
SectionNet Income
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ1 2015
Last reportedQ1 2026
How to read this metric
An increase suggests that the company's partially-owned subsidiaries are performing well, though it reduces the net income available to the parent company.
Detailed definition
This represents the portion of a subsidiary's net income that is attributable to minority shareholders who hold a noncon...
Peer comparison
Standard line item for companies with consolidated subsidiaries that are not 100% owned.
Metric ID:
minority_interestHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.00K | $6.02M | $2.39M | $145.00K | $1.60M | $1.60M | -$584.00K | -$156.00K | -$436.00K | -$24.00K | -$320.00K | -$222.00K | -$580.00K | $937.00K | $359.00K |
| QoQ Change | — | >999% | -60.3% | -93.9% | >999% | +0.5% | -136.4% | +73.3% | -179.5% | +94.5% | <-999% | +30.6% | -161.3% | +261.6% | -61.7% |
| YoY Change | — | — | — | -67.0% | -73.5% | -33.0% | -502.8% | -109.8% | -127.2% | +95.9% | -105.1% | +49.1% | <-999% | +392.8% | +261.7% |
Range-$584.00K – $6.02M
CAGR-5.6%
Avg YoY Growth-211.3%
Median YoY Growth-70.3%
Net Income (NCI) at Other Companies
Frequently Asked Questions
- What is W.R. Berkley's net income (nci)?
- W.R. Berkley (WRB) reported net income (nci) of $359.00K in Q1 2026.
- How has W.R. Berkley's net income (nci) changed year-over-year?
- W.R. Berkley's net income (nci) increased by 261.7% year-over-year, from -$222.00K to $359.00K.
- What does net income (nci) mean?
- The share of a subsidiary's profits that belongs to minority owners rather than the parent company.